ArticleBlood2021
Epigenetic loss of m1A RNA demethylase ALKBH3 in Hodgkin lymphoma targets collagen, conferring poor clinical outcome.
Open access · bronzeAbstract readLetter
In one paragraph
Article in Blood, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 58 citations in OpenAlex.
- Beyond PD-1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next-Generation Immune Strategies.European journal of haematology · 2026Review
- TRMT6-directed mNPJ precision oncology · 2026Article
- The Secret Life of NJournal of molecular biology · 2025Review
- Quantifying the mRNA epitranscriptome reveals epitranscriptome signatures and roles in cancer.Cellular and molecular life sciences : CMLS · 2025Article
- ALKBH3-regulated mActa pharmaceutica Sinica. B · 2025Article
- Biological roles of enhancer RNA m6A modification and its implications in cancer.Cell communication and signaling : CCS · 2025Review
- The importance of physiological and disease contexts in capturing mRNA modifications.Nature structural & molecular biology · 2025Review
- The Role of MClinical reviews in allergy & immunology · 2025Review
- Evaluation of ALKBH2 and ALKBH3 gene regulation in patients with adult T-cell leukemia/lymphoma.Virology journal · 2024Article
- Epigenetics-targeted drugs: current paradigms and future challenges.Signal transduction and targeted therapy · 2024Review
- Decoding the epitranscriptome: a new frontier for cancer therapy and drug resistance.Cell communication and signaling : CCS · 2024Review
- Clinician's Guide to Epitranscriptomics: An Example of NLife (Basel, Switzerland) · 2024Review
- RNA NNature reviews. Urology · 2024Review
- Dysregulation of tRNA methylation in cancer: Mechanisms and targeting therapeutic strategies.Cell death discovery · 2024Review
- The role of RNA epigenetic modification-related genes in the immune response of cattle to mastitis induced by Staphylococcus aureus.Animal bioscience · 2024Article
- Article
- Review
- Small molecule inhibitors targeting mJournal of hematology & oncology · 2024Review
- The Roles of AGTRAP, ALKBH3, DIVERSIN, NEDD8 and RRM1 in Glioblastoma Pathophysiology and Prognosis.Biomedicines · 2024Article
- Histone lactylation-boosted ALKBH3 potentiates tumor progression and diminished promyelocytic leukemia protein nuclear condensates by m1A demethylation of SP100A.Nucleic acids research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 12 institutions in 4 countries.
Rosaura Esteve-PuigJosep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.
Fina ClimentDepartment of Pathology, Bellvitge Biomedical Research Institute (IDIBELL), Hospital Universitari de Bellvitge, Universitat de Barcelona, L'Hospitalet, Barcelona, Spain.
David PiñeyroJosep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.
Eva Domingo-DomènechClinical Hematology Department, Catalan Institute of Oncology (ICO), Hospital Duran i Reynals, L'Hospitalet, Barcelona, Spain.
Veronica DavalosJosep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.
Maite EncuentraClinical Hematology Department, Catalan Institute of Oncology (ICO), Hospital Duran i Reynals, L'Hospitalet, Barcelona, Spain.
Anna ReaJosep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.
Nadia Espejo-HerreraDepartment of Pathology, Bellvitge Biomedical Research Institute (IDIBELL), Hospital Universitari de Bellvitge, Universitat de Barcelona, L'Hospitalet, Barcelona, Spain.
Marta SolerJosep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.
Miguel LopezJosep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.
Vanessa Ortiz-BarahonaJosep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.
Gustavo TapiaDepartment of Pathology, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP) and.
José-Tomás NavarroJosep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.
Joan CidApheresis and Cellular Therapy Unit, Department of Hemotherapy and Hemostasis (ICMHO), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, Barcelona, Spain.
Lourdes FarréProgram Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Alberto VillanuevaProgram Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Isolda CasanovaJosep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.
Ramon ManguesJosep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.
Pablo Santamarina-OjedaNanomaterials and Nanotechnology Research Center-Spanish National Research Council (CINN-CSIC).
Agustín F FernándezNanomaterials and Nanotechnology Research Center-Spanish National Research Council (CINN-CSIC).
Mario F FragaNanomaterials and Nanotechnology Research Center-Spanish National Research Council (CINN-CSIC).
Miguel Angel PirisCentro de Investigación Biomédica en Red (CIBER) de Cáncer (CIBERONC), Madrid, Spain.
Nitzan KolCancer Research Center and.
Chen AvrahamiCancer Research Center and.
Sharon Moshitch-MoshkovitzCancer Research Center and.
Gideon RechaviCancer Research Center and.
Anna SuredaClinical Hematology Department, Catalan Institute of Oncology (ICO), Hospital Duran i Reynals, L'Hospitalet, Barcelona, Spain.
Manel EstellerJosep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.
Josep Carreras Leukaemia Research Institute · ESTel Aviv University · ILConsejo Superior de Investigaciones Científicas · ESInstitut Català d'Oncologia · ESBellvitge University Hospital · ESHospital de Sant Pau · ESInstitut d'Investigació Biomédica de Bellvitge · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESHospital Universitario Fundación Jiménez Díaz · ESInstitució Catalana de Recerca i Estudis Avançats · ESInstitut d'Investigació en Ciències de la Salut Germans Trias i Pujol · ESUniversitat Autònoma de Barcelona · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
DNA MethylationRNA InterferenceRNA Processing, Post-TranscriptionalAlkB Homolog 3, Alpha-Ketoglutarate-Dependent DioxygenaseBase SequenceCell Line, TumorCollagen Type ICollagen Type I, alpha 1 ChainCpG IslandsDatasets as TopicDecitabineDNA, NeoplasmHodgkin DiseaseHumansLeukocytes, MononuclearLymphocytesALKBH3 protein, humanAlkB Homolog 3, Alpha-Ketoglutarate-Dependent DioxygenaseCOL1A2 protein, humanCollagen Type ICollagen Type I, alpha 1 ChainDecitabineDNA, NeoplasmNeoplasm ProteinsRNA, NeoplasmtRNA (adenine(58)-N(1))-methyltransferasetRNA Methyltransferases
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.